# Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia

> **NCT01779167** · PHASE2 · TERMINATED · sponsor: **Weill Medical College of Cornell University** · enrollment: 4 (actual)

## Conditions studied

- Waldenstrom Macroglobulinemia

## Interventions

- **DRUG:** Thalidomide
- **DRUG:** Lenalidomide
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01779167
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-06
- **Primary completion:** 2013-10
- **Final completion:** 2014-04
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Slow Accrual
- **Last updated:** 2018-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01779167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01779167, "Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01779167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*